Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Price Target at $22.60

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $22.60.

Several analysts recently commented on AARD shares. B. Riley Financial began coverage on shares of Aardvark Therapeutics in a research note on Wednesday, January 28th. They set a “buy” rating and a $32.00 target price for the company. William Blair started coverage on shares of Aardvark Therapeutics in a research report on Friday, December 12th. They issued an “outperform” rating on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price target (down from $29.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Friday, March 27th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $6.00 target price (down from $24.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics during the 1st quarter valued at $153,000. Geode Capital Management LLC boosted its holdings in shares of Aardvark Therapeutics by 129.7% during the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock worth $1,851,000 after purchasing an additional 77,327 shares during the period. New York State Common Retirement Fund purchased a new position in Aardvark Therapeutics during the second quarter valued at approximately $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Aardvark Therapeutics during the second quarter valued at approximately $42,000. Finally, Bank of America Corp DE increased its stake in Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after buying an additional 3,369 shares during the period.

Aardvark Therapeutics Price Performance

Shares of AARD stock opened at $4.30 on Wednesday. The stock has a 50-day simple moving average of $8.75 and a 200 day simple moving average of $11.38. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94. The stock has a market capitalization of $93.83 million, a P/E ratio of -1.47 and a beta of 5.33.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.